reviewTop 1% cited

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

British Journal of Dermatology · 2013 · Vol. 168(4) · pp. 844–854

Kim Papp✉(Probity Medical Research)C.E.M. Griffiths(University of Manchester)Kenneth B. Gordon(Northwestern University)Mark Lebwohl(Icahn School of Medicine at Mount Sinai)Philippe Szapary(Janssen (United States))Yasmine Wasfi(Janssen (United States))Daphne Chan(Janssen (United States))M.-C. Hsu(Janssen (United States))Vincent Ho(University of British Columbia)Pierre‐Dominique Ghislain(Cliniques Universitaires Saint-Luc)Bruce Strober(University of Connecticut)Kristian Reich(Dermatologikum Hamburg)on behalf of the PHOENIX 1, PHOENIX 2 and ACCEPT Investigators

View via DOI Publisher page

Abstract

No dose-related or cumulative toxicity was observed with increasing duration of ustekinumab exposure for up to 5 years. Rates of AEs reported in ustekinumab psoriasis trials are generally comparable with those reported for other biologics approved for the treatment of moderate-to-severe psoriasis.

Psoriasis: Treatment and Pathogenesis Autoimmune Bullous Skin Diseases Drug-Induced Adverse ReactionsUstekinumabMedicineMaceAdverse effectPsoriasisPopulationInternal medicineDermatologyDiseaseEnvironmental health

MeSH terms

UstekinumabCardiovascular DiseasesDermatologic AgentsDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansInfectionsMaleMiddle AgedNeoplasmsPsoriasisRandomized Controlled Trials as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as Topic

Citations

406

FWCI

20.26

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial